In the new policy, formulated after detailed stakeholder consultations, 'rare diseases' have not been defined but classified into three groups based on expert opinion.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3whCFhB
via IFTTT
In the new policy, formulated after detailed stakeholder consultations, 'rare diseases' have not been defined but classified into three groups based on expert opinion.
No comments:
Post a Comment